COVID-19 monoclonal antibodies (mAb) are treatments available to people who have tested positive for COVID-19, exhibit mild to moderate symptoms of the disease, and who are at high risk of developing severe COVID-19. When given in the first few days of illness, treatments can prevent hospitalizations and/or severe complications caused by COVID-19.
Our research team is currently conducting telephone surveys of patients who may have tested positive for COVID-19, and experienced symptoms where you would complete telephone surveys at 2 weeks, 4 weeks, and 3 months from the date you diagnosed with COVID-19.
Go to the Participate in mAb Research page, click on "Request to take the survey" under the community members section.
If you think you have COVID-19 or have tested positive, you may be eligible for monoclonal antibody (mAb) treatments. Find information here.
Click here to find information about referring patients for monoclonal antibody (mAb) treatments for COVID-19.
Find information here about participating in research studies around access to and efficacy of monoclonal antibody (mAb) treatments for COVID-19.
The Colorado Department of Public Health & Environment (CDPHE) has issued an urgent advisory regarding the increasing spread of the COVID-19 Delta variant in Colorado.
According to CDPHE, since the first case of the variant in Colorado was identified in early May, it has spread to more than 24 counties throughout the state.
Public health experts say that the Delta variant poses a great risk of future large outbreaks unless we take action now. All health care providers are asked to:
Key updates as of June 18, 2021:
This project is funded by a grant from the National Institutes of Health (NIH) and National Center for Advancing Translational Sciences (NCATS) (award number UL1-TR002535-03S3).